SB-773812 Administered In Adults With Schizophrenia
Public ClinicalTrials.gov record NCT00259870. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia
Study identification
- NCT ID
- NCT00259870
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 338 participants
Conditions and interventions
Conditions
Interventions
- SB-773812 Drug
- Olanzapine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2005
- Primary completion
- Not listed
- Completion
- Jul 31, 2007
- Last update posted
- Mar 22, 2017
2005 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35233 | — |
| GSK Investigational Site | Cerritos | California | 90703 | — |
| GSK Investigational Site | Garden Grove | California | 92845 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | San Diego | California | 92126 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | New Haven | Connecticut | 06519 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| GSK Investigational Site | North Miami | Florida | 33161 | — |
| GSK Investigational Site | Clementon | New Jersey | 08021 | — |
| GSK Investigational Site | Kenilworth | New Jersey | 07033 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87108 | — |
| GSK Investigational Site | Orangeburg | New York | 10962 | — |
| GSK Investigational Site | Butner | North Carolina | 27509 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45267 | — |
| GSK Investigational Site | Bellaire | Texas | 77401 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Falls Church | Virginia | 22041 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00259870, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2017 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00259870 live on ClinicalTrials.gov.